Debrisoquine oxidation phenotype and susceptibility to lung cancer [letter; comment

Abstract

British Journal of Clinical PharmacologyVolume 30, Issue 4 p. 653-656 Free Access Debrisoquine oxidation phenotype and susceptibility to lung cancer [letter; comment] AR Boobis, AR Boobis Academic Department of Medicine, Royal Free Hospital School of Medicine, London.Search for more papers by this authorDS Davies, DS Davies Academic Department of Medicine, Royal Free Hospital School of Medicine, London.Search for more papers by this author AR Boobis, AR Boobis Academic Department of Medicine, Royal Free Hospital School of Medicine, London.Search for more papers by this authorDS Davies, DS Davies Academic Department of Medicine, Royal Free Hospital School of Medicine, London.Search for more papers by this author First published: October 1990 https://doi.org/10.1111/j.1365-2125.1990.tb03832.xCitations: 5AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References Alván, G., Bechtel, P., Iselius, L. & Stevier, E. (1990). Do European populations differ with respect to frequency of the phenotype slow debrisoquine oxidation? Eur. J. clin. Pharmac. (in press). Ayesh, R., Idle, J. R., Ritchie, J. C., Crothers, M. J. & Hetzel, M. R. (1984). Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature, 312, 169– 170. Boobis, A. R., Speirs, C. J., Murray, S. & Davies, D. S. (1987). Potency and reversibility of quinidine inhibition of debrisoquine 4-hydroxylase activity in man. Abstr. Xth International Congress of Pharmacology, Sydney, Australia, 23–28 August, O335. Caporaso, N. & Idle, J. R. (1990). The rationale for case-control methodology in epidemiological studies of cancer risk (response to Speirs et al. 1990). Br. J. clin. Pharmac., 30, 149– 150. Caporaso, N., Hayes, R. B., Dosemeci, M., Hoover, R., Ayesh, R., Hetzel, M. & Idle, J. (1989a). Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. Cancer Res., 49, 3675– 3679. Caporaso, N., Hoover, R., Resau, J., Trump, B., Issaq, H., Muschik, G. & Harris, C. (1988). Debrisoquine metabolic phenotype and the risk of lung cancer. American Society of Clinical Oncology. 24th Annual Meeting, 7, 336. Caporaso, N., Pickle, L. W., Bale, S., Ayesh, R., Hetzel, M. & Idle, J. (1989b). The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk. Genet. Epidemiol., 6, 517– 524. Idle, J. R., Mahgoub, A., Lancaster, R. & Smith, R. L. (1978). Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sci., 22, 979– 984. Law, M. R. (1990). Genetic predisposition to lung cancer. Br. J. Cancer, 61, 195– 206. Law, M. R., Hetzel, M. R. & Idle, J. R. (1989). Debrisoquine metabolism and genetic predisposition to lung cancer. Br. J. Cancer, 59, 686– 687. Lee, E. J. D. (1988). Diurnal effects on debrisoquine hydroxylation phenotyping. Eur. J. clin. Pharmac., 35, 441– 442. Murray, S. & Waddell, K. A. (1982). The electron capture negative ion chemical ionisation mass spectra of 2-(4′,6′-bistrifluoromethyl-2′-pyrimidinyl)tetrahydroisoquinoline and 4-substituted analogues. Biomed. Mass Spectrom., 9, 466– 472. Philip, P. A., James, C. A. & Rogers, H. J. (1987). Determination of metabolic ratio from hourly urine collections in healthy volunteers. Br. J. clin. Pharmac., 24, 827– 829. Evans, Price D. A., Mahgoub, A., Sloan, T. P., Idle, J. R. & Smith, R. L. (1980). A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. med. Genet., 17, 102– 105. Roots, I., Drakoulis, N., Ploch, M., Heinemeyer, G., Loddenkemper, R., Minks, T., Nitz, M., Otte, F. & Koch, M. (1988). Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk. Klin. Wochenschr. (Suppl. XI), 66, 87– 97. Silas, J. H., Lennard, M. S., Tucker, G. T., Smith, A. J., Malcolm, S. L. & Marten, T. R. (1978). The disposition of debrisoquine in hypertensive patients. Br. J. clin. Pharmac., 5, 27– 34. Speirs, C. J., Murray, S., Boobis, A. R., Seddon, C. E. & Davies, D. S. (1986). Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br. J. clin. Pharmac., 22, 739– 743. Speirs, C. J., Murray, S., Davies, D. S., Mabadeje, A. F. B. & Boobis, A. R. (1990). Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br. J. clin. Pharmac., 29, 101– 109. Steiner, E., Bertilsson, L., Säwe, J., Bertling, I. & Sjöqvist, F. (1988). Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin. Pharmac. Ther., 44, 431– 435. Steiner, E., Iselius, L., Alván, G., Lindsten, J. & Sjöqvist, F. (1985). A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquine. Clin. Pharmac. Ther., 38, 394– 401. Citing Literature Volume30, Issue4October 1990Pages 653-656 ReferencesRelatedInformation